Are investors shorting Arsanis?

Arsanis saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 20,200 shares, a drop of 14.4% from the March 15th total of 23,600 shares. Based on an average daily trading volume, of 35,900 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.8% of the shares of the stock are short sold. View Arsanis' Short Interest .

When is Arsanis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ASNS earnings forecast .

How were Arsanis' earnings last quarter?

Arsanis, Inc. (NASDAQ:ASNS) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.67) earnings per share for the quarter. The company had revenue of $1.02 million for the quarter. Arsanis had a negative trailing twelve-month return on equity of 667.48% and a negative net margin of 112.13%.

When did Arsanis' stock split?

Arsanis shares reverse split on Wednesday, April 19th 2023. The 1-10 reverse split was announced on Wednesday, April 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Arsanis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arsanis investors own include Catalyst Pharmaceuticals (CPRX) , NxStage Medical (NXTM) , Selecta Biosciences (SELB) , CDTi Advanced Materials (CDTI) , Curis (CRIS) , bluebird bio (BLUE) , Juno Therapeutics (JUNO) , Nektar Therapeutics (NKTR) , Tocagen (TOCA) .

When did Arsanis IPO?

Arsanis (ASNS) raised $15 million in an IPO on Friday, May 13th 2022. The company issued 3,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO.

NASDAQ:ASNS

Arsanis (ASNS) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ASNS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.67
▼
$0.70
50-Day Range: $3.11
▼
$3.11
52-Week Range: $1.15
▼
$28.69

Volume: 3,641 shs
Average Volume: 14,632 shs
Market Capitalization: $2.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Earnings Headlines Insider Trades Short Interest Social Media

Get Arsanis alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Arsanis Stock (NASDAQ:ASNS)

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ASNS Stock News Headlines

April 4, 2024 | globenewswire.com

Actelis Networks and Khushi Communications Partner to Enable Expansion of IoT Networks Throughout India

March 26, 2024 | globenewswire.com

Actelis Networks Reports Fiscal Full Year 2023 Results

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

March 12, 2024 | finance.yahoo.com

Actelis Networks and Netceed Sign Partnership Agreement to Extend Actelis’ Hybrid-Fiber Networking Solutions to Netceed’s North American Customer Base

February 29, 2024 | globenewswire.com

Actelis Achieves National Institute of Standards and Technology (NIST) Certification for Data Cyber Security

February 7, 2024 | finance.yahoo.com

Actelis Networks Announces New $1.5 Million Credit Line

February 1, 2024 | finance.yahoo.com

Actelis Receives Order For City of Napa Intelligent Traffic Management System

January 16, 2024 | finance.yahoo.com

Actelis Announces U.S. Department of Defense JITC Labs Approval for Cybersecurity and Interoperability and Approved Products List Status

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

December 28, 2023 | finance.yahoo.com

Actelis Receives Order From Major North American Rail Operator For Management Software And Services

December 20, 2023 | finance.yahoo.com

Actelis Networks Announces Closing of $1.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

December 18, 2023 | finance.yahoo.com

Actelis Networks Announces $1.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

December 14, 2023 | finance.yahoo.com

Actelis Announces Order Received and Launch of New Last Mile Hybrid-Fiber Multi-Gigabit Broadband Solution For Buildings and IoT Applications

December 7, 2023 | morningstar.com

Actelis Networks Inc ASNS

December 6, 2023 | finance.yahoo.com

Actelis Receives Order For Networking Of Traffic Management and Safety IoT Applications In The City of Everett, Washington

November 29, 2023 | finance.yahoo.com

Actelis Receives Order From Major German Energy Provider For Encrypted, Cyber-Hardened, Hybrid-Fiber Networking

November 20, 2023 | finance.yahoo.com

Actelis Delivers Hybrid-Fiber Networking Solutions to US Naval Base In Asia-Pacific

November 14, 2023 | finance.yahoo.com

Actelis Networks Reports Third Quarter 2023

October 24, 2023 | finance.yahoo.com

Actelis Launches Unique, Ultra Low Power In-Building Gigabit Connectivity Solution For Instant Service Provisioning of Multi-Tenant Units

October 17, 2023 | finance.yahoo.com

Actelis Selected and Receives First Order to Provide IoT Networking To European Natural Gas System Operator

September 27, 2023 | finance.yahoo.com

Actelis Achieves Third Party Validation For FIPS Cyber Protection Standard Required by Government Agencies

August 28, 2023 | finance.yahoo.com

Actelis to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

August 26, 2023 | seekingalpha.com

ASNS Actelis Networks, Inc.

August 24, 2023 | finance.yahoo.com

Actelis Networks Reports Second Quarter 2023

August 14, 2023 | finance.yahoo.com

U.S. Air Force Selects Actelis for IoT Networking Modernization of a Major Air Force Base

August 11, 2023 | investing.com

X4 Pharmaceuticals (XFOR) Earnings Dates & Reports

August 9, 2023 | finance.yahoo.com

Actelis Receives Orders for Its Hybrid Copper Networking Solutions To Expedite IoT Modernization of Major Highway and Rail Systems Throughout Japan

See More Headlines

Receive ASNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arsanis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Computer and Technology
Industry: Communications equipment, not elsewhere classified
Sub-Industry: N/A
Current Symbol: NASDAQ:ASNS
CUSIP: N/A
CIK: 1501697
Web: www.arsanis.com
Phone: (857) 529-8300
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,290,000.00
Net Margins: -112.13%
Pretax Margin: -112.13%
Return on Equity: -667.48%
Return on Assets: -52.43%

Debt

Debt-to-Equity Ratio: 13.77
Current Ratio: 0.86
Quick Ratio: 0.49

Sales & Book Value

Annual Sales: $5.61 million
Price / Sales: 0.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.08 per share
Price / Book: 8.50

Miscellaneous

Outstanding Shares: 3,020,000
Free Float: 2,591,000
Market Cap: $2.05 million
Optionable: Not Optionable
Beta: 0.79

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Paula S. Ragan
President, Chief Executive Officer & Director
Adam S. Mostafa
Chief Financial Officer & Treasurer
Celeste DiJohnson
Vice President-Clinical Operations
Mary DiBiase
Vice President-Technical Operations & Quality
Tarek Ebrahim
Vice President-Medical Affairs & Rare Disease

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ASNS Stock Analysis - Frequently Asked Questions

Are investors shorting Arsanis?: Arsanis saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 20,200 shares, a drop of 14.4% from the March 15th total of 23,600 shares. Based on an average daily trading volume, of 35,900 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.8% of the shares of the stock are short sold.
View Arsanis' Short Interest.
When is Arsanis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ASNS earnings forecast.
How were Arsanis' earnings last quarter?: Arsanis, Inc. (NASDAQ:ASNS) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.67) earnings per share for the quarter. The company had revenue of $1.02 million for the quarter. Arsanis had a negative trailing twelve-month return on equity of 667.48% and a negative net margin of 112.13%.
When did Arsanis' stock split?: Arsanis shares reverse split on Wednesday, April 19th 2023. The 1-10 reverse split was announced on Wednesday, April 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Arsanis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arsanis investors own include Catalyst Pharmaceuticals (CPRX), NxStage Medical (NXTM), Selecta Biosciences (SELB), CDTi Advanced Materials (CDTI), Curis (CRIS), bluebird bio (BLUE), Juno Therapeutics (JUNO), Nektar Therapeutics (NKTR), Tocagen (TOCA).
When did Arsanis IPO?: Arsanis (ASNS) raised $15 million in an IPO on Friday, May 13th 2022. The company issued 3,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO.

This page (NASDAQ:ASNS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arsanis (ASNS) Stock Price, News & Analysis

About Arsanis Stock (NASDAQ:ASNS)

ASNS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

ASNS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info